The WAHA trial (Walnuts and Healthy Ageing), a randomised controlled trial of 636 adults aged 63 to 79 followed for 2 years, found that daily walnut consumption equivalent to half a cup reduced LDL cholesterol by 4 percent and significantly reduced levels of small, dense LDL particles, the most atherogenic LDL subtype. A companion neuroimaging sub-study found attenuated brain ageing in the walnut group, measured by MRI.
What Makes Walnuts Different from Other Nuts
- Alpha-linolenic acid: walnuts are the richest nut source of plant omega-3, containing 2.5g per 30g serving; ALA converts to EPA and DHA and reduces inflammatory eicosanoid production
- Ellagitannins: polyphenols found almost exclusively in walnuts among common nuts; converted by gut bacteria to urolithins, which have anti-inflammatory and cancer-preventive properties in human studies
- Arginine: the amino acid precursor to nitric oxide; the arginine density in walnuts contributes to their endothelium-protective effects
- Gamma-tocopherol: the form of vitamin E dominant in walnuts; inhibits nitrosamine formation and has anti-inflammatory properties distinct from alpha-tocopherol
The Dose
Most clinical trials use 30 to 45 grams of walnuts daily (approximately 7 to 10 whole walnuts). The PREDIMED trial, which found 30 percent reduction in cardiovascular events in the Mediterranean diet group, included 30g of mixed nuts daily with walnuts as the primary component. A small daily portion appears to capture the majority of the cardiovascular benefit.